The therapeutic potential of ADAM15

Current Pharmaceutical Design

Volumn 15, Issue 20, 2009, Pages 2311-2318

  Lucas, Neali ^a   Najy, Abdo J ^a   Day, Mark L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ADAM15; ADAMs; Cancer; Inflammation; Metargidin; Proteinase

Indexed keywords

ADAM PROTEIN; ADAM15 INHIBITOR; ADAM15 PROTEIN; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INCB 3619; INCB 7839; METALLOPROTEINASE INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT HUMAN ADAM15 DISINTEGRIN DOMAIN; RECOMBINANT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BREAST CANCER; CANCER GROWTH; CATALYSIS; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; UPREGULATION;

ADAM PROTEINS; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; NEOPLASMS;

EID: 69249117409     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682370     Document Type: Review

References (81)

1. Edwards DR, Handsley MM, Pennington CJ. The ADAM metallo-proteinases. Mol Aspects Med 2008; 29: 258-89.
2. Gutierrez JM, Rucavado A. Snake venom metalloproteinases: Their role in the pathogenesis of local tissue damage. Biochimie 2000; 82: 841-50
3. Siigur J, Tonismagi K, Trummal K, Aaspollu A, Samel M, Vija H, et al. Vipera lebetina venom contains all types of snake venom metalloproteases. Pathophysiol Haemost Thromb 2005; 34: 209-14.
4. McCulloch DR, Harvey M, Herington AC. The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 2000; 167: 11-21.
5. Primakoff P, Myles DG. The ADAM gene family: Surface proteins with adhesion and protease activity. Trends Genet 2000; 16: 83-7.
6. Kratzschmar J, Lum L, Blobel CP. Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence. J Biol Chem 1996; 271: 4593-6.
7. Herren B, Raines EW, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997; 11: 173-80.
8. Murphy G. The ADAMs: Signalling scissors in the tumour micro-environment. Nat Rev Cancer 2009; 8: 929-41.
9. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000; 80: 931-42.
10. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46: 222-32.
11. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, et al. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 2001; 46: 184-90.
12. Glinsky GV, Krones-Herzig A, Glinskii AB. Malignancy-associated regions of transcriptional activation: Gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. Neoplasia 2003; 5: 218-28.
13. Karkkainen I, Karhu R, Huovila AP. Assignment of the ADAM15 gene to human chromosome band 1q21.3 by in situ hybridization. Cytogenet Cell Genet 2000; 88: 206-7.
14. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006; 8: 319-29.
15. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 2008; 68: 1092-9.
16. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005; 131: 41-8.
17. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008; 68: 7083-9.
18. Schutz A, Hartig W, Wobus M, Grosche J, Wittekind C, Aust G. Expression of ADAM15 in lung carcinomas. Virchows Arch 2005; 446: 421-9.
19. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005; 26: 17-24.
20. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-65.
21. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 515-23.
22. Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, et al. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 2003; 23: 5614-24.
23. Ham C, Levkau B, Raines EW, Herren B. ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherin. Exp Cell Res 2002; 279: 239-47.
24. Koch AE.IReview: Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41: 951-62.
25. Komiya K, Enomoto H, Inoki I, Okazaki S, Fujita Y, Ikeda E, et al. Expression of ADAM15 in rheumatoid synovium: Up-regulation by vascular endothelial growth factor and possible implications for angiogenesis. Arthritis Res Ther 2005; 7: R1158-73.
26. Martin J, Eynstone LV, Davies M, Williams JD, Steadman R. The role of ADAM 15 in glomerular mesangial cell migration. J Biol Chem 2002; 277: 33683-9.
27. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
28. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000; 6(Suppl 3): S245-9.
29. Kim S, Harris M, Varner JA. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000; 275: 33920-8.
30. Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res 2001; 52: 372-86.
31. Charrier-Hisamuddin L, Laboisse CL, Merlin D. ADAM-15: A metalloprotease that mediates inflammation. FASEB J 2008; 22: 641-53.
32. Maton A. Human Biology and Health, Prentice Hall 1993.
33. Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM, et al. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 2003; 89: 808-23.
34. Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, et al. Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 1999; 112 (Pt 4): 579-87.
35. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem 1998; 273: 7345-50.
36. Langer H, May AE, Bultmann A, Gawaz M. ADAM 15 is an adhesion receptor for platelet GPIIb-IIIa and induces platelet activation. Thromb Haemost 2005; 94: 555-61.
37. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
38. Bohm BB, Aigner T, Blobel CP, Kalden JR, Burkhardt H. Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. Arthritis Rheum 2001; 44: 2046-54.
39. Bohm BB, Aigner T, Gehrsitz A, Blobel CP, Kalden JR, Burkhardt H. Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum 1999; 42: 1946-50.
40. Bohm BB, Aigner T, Roy B, Brodie TA, Blobel CP, Burkhardt H. Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. Arthritis Rheum 2005; 52: 1100-9.
41. Bohm BB, Schirner A, Burkhardt H. Adam15 Modulates Outside-in Signaling in Chondrocyte-Matrix Interactions. J Cell Mol Med 2008; In press.
42. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006; 291: C1-10.
43. Schafer B, Marg B, Gschwind A, Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 2004; 279: 47929-38.
44. Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L, et al. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem 2005; 386: 845-55.
45. Boscher C, Mege RM. Cadherin-11 interacts with the FGF receptor and induces neurite outgrowth through associated downstream signalling. Cell Signal 2008; 20: 1061-72.
46. Schafer S, Koch PJ, Franke WW. Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins. Exp Cell Res 1994; 211: 391-9.
47. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002; 2: 301-14.
48. Najy AJ, Day KC, Day ML. The ectodomain shedding of Ecadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008; 283: 18393-401.
49. Nourry C, Grant SG, Borg JP. PDZ domain proteins: Plug and play! Sci STKE 2003; 2003: RE7.
50. Howard L, Nelson KK, Maciewicz RA, Blobel CP. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. J Biol Chem 1999; 274: 31693-9.
51. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM, et al. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem 2003; 278: 16844-51.
52. Tanaka M, Nanba D, Mori S, Shiba F, Ishiguro H, Yoshino K, et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 2004; 279: 41950-9.
53. Poghosyan Z, Robbins SM, Houslay MD, Webster A, Murphy G, Edwards DR. Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J Biol Chem 2002; 277: 4999-5007.
54. Susva M, Missbach M, Green J. Src inhibitors: Drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 2000; 21: 489-95
55. Frame MC. Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114-30.
56. Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 2005; 19: 1522-4.
57. Ehrnsperger A, Rehli M, Thu-Hang P, Kreutz M. Epigenetic regulation of the dendritic cell-marker gene ADAM19. Biochem Biophys Res Commun 2005; 332: 456-64.
58. Kleino I, Ortiz RM, Huovila AP. ADAM15 gene structure and differential alternative exon use in human tissues. BMC Mol Biol 2007; 8: 90.
59. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin Cell Dev Biol 2009; 20: 138-45.
60. Shimizu E, Yasui A, Matsuura K, Hijiya N, Higuchi Y, Yamamoto S. Structure and expression of the murine ADAM 15 gene and its splice variants, and difference of interaction between their cytoplasmic domains and Src family proteins. Biochem Biophys Res Commun 2003; 309: 779-85.
61. Yasui A, Matsuura K, Shimizu E, Hijiya N, Higuchi Y, Yamamoto S. Expression of splice variants of the human ADAM15 gene and strong interaction between the cytoplasmic domain of one variant and Src family proteins Lck and Hck. Pathobiology 2004; 71: 185-92.
62. Zhong JL, Poghosyan Z, Pennington CJ, Scott X, Handsley MM, Warn A, et al. Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol Cancer Res 2008; 6: 383-94
63. Milla ME, Leesnitzer MA, Moss ML, Clay WC, Carter HL, Miller AB, et al. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J Biol Chem 1999; 274: 30563-70.
64. Lum L, Reid MS, Blobel CP. Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J Biol Chem 1998; 273: 26236-47.
65. Herren B, Garton KJ, Coats S, Bowen-Pope DF, Ross R, Raines EW. ADAM15 overexpression in NIH3T3 cells enhances cell-cell interactions. Exp Cell Res 2001; 271: 152-60.
66. Thomas G. Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3: 753-66.
67. Moss ML, Stoeck A, Yan W, Dempsey PJ. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 2008; 9: 2-8.
68. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007; 13: 1892-902.
69. Liu X, Fridman JS, Wang Q, Caulder E, Yang G, Covington M, et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006; 5: 648-56.
70. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50
71. Holbro T, Hynes NE. ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195-217.
72. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002; 11: 2615-24.
73. Zhao J, Chen H, Peschon JJ, Shi W, Zhang Y, Frank SJ, et al. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 2001; 232: 204-18.
74. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995; 131: 275-8.
75. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem 1998; 273: 16993-7.
76. Smith KM, Gaultier A, Cousin H, Alfandari D, White JM, DeSimone DW. The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol 2002; 159: 893-902.
77. Blobel CP, Myles DG, Primakoff P, White JM. Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence. J Cell Biol 1990; 111: 69-78.
78. Wolfsberg TG, Bazan JF, Blobel CP, Myles DG, Primakoff P, White JM. The precursor region of a protein active in sperm-egg fusion contains a metalloprotease and a disintegrin domain: Structural, functional, and evolutionary implications. Proc Natl Acad Sci USA 1993; 90: 10783-7.
79. White JM. ADAMs: Modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003; 15: 598-606.
80. Klessner JL, Desai BV, Amargo EV, Getsios S, Green KJ. EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol Biol Cell 2009; 20: 328-37.
81. Maretzky T, Yang G, Ouerfelli O, Overall CM, Worpenberg S, Hassiepen U, et al. Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays. Biochem J 2009; 420: 105-13.